Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Goodkin

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Archives of Neurology|March 1, 1992
Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence, or measurement artifact?D E Goodkin, J S Ross, S V Medendorp, et al.
Archives of Neurology|November 1, 1994
Serum cobalamin deficiency is uncommon in multiple sclerosisD E Goodkin, D W Jacobsen, N Galvez, et al.
Archives of Neurology|August 2, 2001
Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosisD C Mohr, D E Goodkin, J Islar, et al.
Magnetic Resonance Imaging|December 7, 2002
3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brainD Pelletier, S J Nelson, D Grenier, et al.
Neurology|May 10, 2000
Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1aM Kita, D E Goodkin, P Bacchetti, et al.
Neurology|April 1, 1992
Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research GroupD E Goodkin, D Cookfair, K Wende, et al.
Annals of Neurology|July 13, 1999
Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials. National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple SclerosisD E Goodkin, S Reingold, W Sibley, et al.
Neurology|November 1, 1996
Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIsD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.
Magnetic Resonance Imaging|February 20, 2003
T2 relaxation time histograms in multiple sclerosisD Grenier, D Pelletier, M Normandeau, et al.
Journal of Behavioral Medicine|August 1, 1997
Identification of Beck Depression Inventory items related to multiple sclerosisD C Mohr, D E Goodkin, W Likosky, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Archives of Neurology|March 1, 1992
Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence, or measurement artifact?D E Goodkin, J S Ross, S V Medendorp, et al.
Archives of Neurology|November 1, 1994
Serum cobalamin deficiency is uncommon in multiple sclerosisD E Goodkin, D W Jacobsen, N Galvez, et al.
Archives of Neurology|August 2, 2001
Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosisD C Mohr, D E Goodkin, J Islar, et al.
Magnetic Resonance Imaging|December 7, 2002
3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brainD Pelletier, S J Nelson, D Grenier, et al.
Neurology|May 10, 2000
Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1aM Kita, D E Goodkin, P Bacchetti, et al.
Neurology|April 1, 1992
Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research GroupD E Goodkin, D Cookfair, K Wende, et al.
Annals of Neurology|July 13, 1999
Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials. National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple SclerosisD E Goodkin, S Reingold, W Sibley, et al.
Neurology|November 1, 1996
Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIsD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.
Magnetic Resonance Imaging|February 20, 2003
T2 relaxation time histograms in multiple sclerosisD Grenier, D Pelletier, M Normandeau, et al.
Journal of Behavioral Medicine|August 1, 1997
Identification of Beck Depression Inventory items related to multiple sclerosisD C Mohr, D E Goodkin, W Likosky, et al.
Pageof 9